No significant associations were found between KL-VS heterozygosity and levels of any of the 3 CSF AD biomarkers in the entire cohort (Aβ42: β = 0.114; 95% CI, −0.258 to 0.030; P = .12; T-tau: β = −0.044; 95% CI, −0.248 to 0.160; P = .67; P-tau: β = 0.360; 95% CI, −0.127 to 0.199; P = .68) or when stratified by clinical groups or APOE4 status. Here, MAPT is linked to Alzheimer disease.